Amgen

Biotechnology
AMGN
$ 278 (2.8)%
Share price
$ 149 bn
Market Cap
$ 204 bn
Enterprise Value

Carbon footprint

1.2 Ton
GHG emissions per $ 1 mln investment
0.04x the weighted average for S&P 500
FY2020
How is this calculated?
-2.4%
YOY change in GHG emissions
Weaker than the -11% weighted average for S&P 500
FY2020 vs. previous year

Primary Climate Goal

This company has not set a company-wide target for an absolute reduction in GHG emissions yet

but has a science based goal that does not target absolute reductions but is still aligned with Paris Agreement according to SBTi

GHG emissions and Carbon intensity

Amgen's GHG emissions (market-based) (Kt of CO2e)

Amgen's carbon footprint

Amgen reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y).

Amgen's Scope 3 emissions decreased to 2,627 Kt (-147 /-5.3% y-o-y). There has been no clear trend lately.

The company has not set a company-wide target for an absolute reduction in GHG emissions yet.

Amgen also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Amgen commits to reduce absolute scope 1 and 2 GHG emissions 55% by 2027 from a 2019 base year. Amgen also commits to increase annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, to continue annually sourcing of 100% renewable electricity through 2030. Amgen further commits that 73% of its suppliers by spend covering upstream purchased goods and services and capital goods will have science- based targets by 2027.

Company environmental metrics

Show more...